OptiNose (OPTN)
(Delayed Data from NSDQ)
$0.80 USD
+0.05 (6.67%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $0.80 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.80 USD
+0.05 (6.67%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $0.80 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth F Momentum F VGM
Zacks News
OptiNose (OPTN) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
OptiNose (OPTN) delivered earnings and revenue surprises of -4.55% and 4.09%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
OptiNose (OPTN) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
by Zacks Equity Research
OptiNose (OPTN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is NuCana PLC Sponsored ADR (NCNA) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how NuCana PLC Sponsored ADR (NCNA) and OptiNose (OPTN) have performed compared to their sector so far this year.
Zacks.com featured highlights include: SunOpta, Lazydays, Quotient, OptiNose and Motorcar Parts of America
by Zacks Equity Research
Zacks.com featured highlights include: SunOpta, Lazydays, Quotient, OptiNose and Motorcar Parts of America
Rising P/E: An Overlooked Trick to Land on 5 Winning Stocks
by Sanghamitra Saha
Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.
OptiNose (OPTN) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
OptiNose (OPTN) has been struggling lately, but the selling pressure may be coming to an end soon.
After Plunging 44.2% in 4 Weeks, Here's Why the Trend Might Reverse for OptiNose (OPTN)
by Zacks Equity Research
The heavy selling pressure might have exhausted for OptiNose (OPTN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
OptiNose (OPTN) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
OptiNose (OPTN) delivered earnings and revenue surprises of 13.51% and -8.68%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Will OptiNose (OPTN) Report Negative Q3 Earnings? What You Should Know
by Zacks Equity Research
OptiNose (OPTN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OptiNose (OPTN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
OptiNose (OPTN) delivered earnings and revenue surprises of -2.33% and 5.84%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
OptiNose (OPTN) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
OptiNose (OPTN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OptiNose (OPTN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
OptiNose (OPTN) delivered earnings and revenue surprises of 5.77% and 4.90%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
OptiNose (OPTN) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
OptiNose (OPTN) delivered earnings and revenue surprises of -2.22% and -10.41%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
OptiNose (OPTN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
OptiNose (OPTN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OptiNose (OPTN) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
OptiNose (OPTN) delivered earnings and revenue surprises of -9.80% and -1.04%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Moving Average Crossover Alert: OptiNose
by Zacks Equity Research
OptiNose, Inc. (OPTN) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.
OptiNose (OPTN) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
OptiNose (OPTN) delivered earnings and revenue surprises of 13.43% and -11.00%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: OptiNose (OPTN) Q4 Earnings Expected to Decline
by Zacks Equity Research
OptiNose (OPTN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: OptiNose (OPTN) Q3 Earnings Expected to Decline
by Zacks Equity Research
OptiNose (OPTN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OptiNose (OPTN) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
OptiNose (OPTN) delivered earnings and revenue surprises of 12.00% and -13.69%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate OptiNose (OPTN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
OptiNose (OPTN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OptiNose (OPTN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
OptiNose (OPTN) delivered earnings and revenue surprises of 1.41% and 2.99%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
OptiNose (OPTN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
OptiNose (OPTN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OptiNose (OPTN) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
OptiNose (OPTN) delivered earnings and revenue surprises of 10.29% and 21.15%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?